Epoprostenol therapy for pulmonary arterial hypertension

Satoshi Akagi, Kazufumi Nakamura, Hiromi Matsubara, Aiko Ogawa, Toshihiro Sarashina, Kentaro Ejiri, Hiroshi Ito

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalActa medica Okayama
Volume69
Issue number3
Publication statusPublished - 2015

Keywords

  • Complications
  • Epoprostenol
  • High-dose
  • Pulmonary arterial hypertension
  • Side effects

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Epoprostenol therapy for pulmonary arterial hypertension'. Together they form a unique fingerprint.

  • Cite this